- Home
- MLTX
as of 01-16-2026 3:40pm EST
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
| Founded: | 2021 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 979.8M | IPO Year: | N/A |
| Target Price: | $22.22 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.95 - $62.75 | Next Earning Date: | 02-25-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered MLTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of MoonLake Immunotherapeutics (MLTX)
Chief Executive Officer
Avg Cost/Share
$14.49
Shares
70,000
Total Value
$1,014,300.00
Owned After
2,878,577
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$14.43
Shares
72,908
Total Value
$1,052,062.44
Owned After
0
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$15.08
Shares
130,000
Total Value
$1,960,400.00
Owned After
2,878,577
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$15.08
Shares
130,000
Total Value
$1,960,400.00
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | MLTX | Chief Executive Officer | Dec 9, 2025 | Sell | $14.49 | 70,000 | $1,014,300.00 | 2,878,577 | |
| Reich Kristian | MLTX | Chief Scientific Officer | Dec 9, 2025 | Sell | $14.43 | 72,908 | $1,052,062.44 | 0 | |
| Santos da Silva Jorge | MLTX | Chief Executive Officer | Dec 8, 2025 | Sell | $15.08 | 130,000 | $1,960,400.00 | 2,878,577 | |
| Reich Kristian | MLTX | Chief Scientific Officer | Dec 8, 2025 | Sell | $15.08 | 130,000 | $1,960,400.00 | 0 |
Compare MLTX vs Leading Stocks
See how MLTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MLTX MoonLake Immunotherapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.